> Pharmaceutical Litigation > Aricept 23

Aricept 23

Aricept originally came on the market as a 10 mg dosage drug to treat Alzheimer’s disease. With their patent about to expire in 2010, Aricept’s manufacturer, Eisai, released a new version of the drug: Aricept 23.

Aricept 23 is the same formulation, but the dose is higher: 23 mg. Because of this, the FDA granted Eisai a 3-year extension on their patent. That meant 3 more years without competition from generic brands.

Profit Over Safety?

This change carried little added benefit to Alzheimer’s patients and their families, yet it meant an increase in serious, life-threatening risks. While the trials of Aricept 23 showed some improvement in cognition – although no real improvement in day-to-day functioning – they also demonstrated a significant increase in nausea and vomiting.

Severe and frequent vomiting may lead to:

  • Pneumonia
  • Massive gastrointestinal bleeding
  • Esophageal rupture

These complications can be fatal.

Contact Us

Aricept 23 is an example of a drug company putting profit above the safety of patients. If your loved one has been injured or lost their life after taking Aricept 23, you deserve compensation for your loss. The attorneys at the Law Offices of Brian D. Witzer are dedicated to seeking justice for those harmed by Aricept 23.

Contact us today by calling (888) WITZER-6 for a free, no-obligation consultation.

Have you received medical attention?

Were there witnesses to your incident?

Do you have legal representation?